These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
582 related articles for article (PubMed ID: 15218318)
1. Abuse of recombinant human growth hormone: studies in two different dog models. Rigamonti AE; Scanniffio D; Bonomo SM; Cella SG; Sartorio A; Müller EE Neuroendocrinology; 2004; 79(5):237-46. PubMed ID: 15218318 [TBL] [Abstract][Full Text] [Related]
2. Testosterone inhibition of growth hormone release stimulated by a growth hormone secretagogue: studies in the rat and dog. Rigamonti AE; Cella SG; Giordani C; Bonomo SM; Giunta M; Sartorio A; Muller E Neuroendocrinology; 2006; 84(2):115-22. PubMed ID: 17106185 [TBL] [Abstract][Full Text] [Related]
3. GH and cortisol rebound rise during and following a somatostatin infusion: studies in dogs with the use of a GH-releasing peptide. Rigamonti AE; Bonomo SM; Cella SG; Müller EE J Endocrinol; 2002 Sep; 174(3):387-94. PubMed ID: 12208658 [TBL] [Abstract][Full Text] [Related]
4. Growth hormone (GH) rebound rise following somatostatin infusion withdrawal: studies in dogs with the use of GH-releasing hormone and a GH-releasing peptide. Rigamonti AE; Cavallera G; Bonomo S; Deghenghi R; Locatelli V; Cella SG; Müller EE Eur J Endocrinol; 2001 Nov; 145(5):635-44. PubMed ID: 11720883 [TBL] [Abstract][Full Text] [Related]
5. Gender differences in growth hormone response to exercise before and after rhGH administration and the effect of rhGH on the hormone profile of fit normal adults. Giannoulis MG; Boroujerdi MA; Powrie J; Dall R; Napoli R; Ehrnborg C; Pentecost C; Cittadini A; Jørgensen JO; Sonksen PH; Clin Endocrinol (Oxf); 2005 Mar; 62(3):315-22. PubMed ID: 15730413 [TBL] [Abstract][Full Text] [Related]
6. Effect of withdrawal of somatostatin plus GH-releasing hormone as a stimulus of GH secretion in obesity. Alvarez P; Isidro L; Leal-Cerro A; Casanueva FF; Dieguez C; Cordido F Clin Endocrinol (Oxf); 2002 Apr; 56(4):487-92. PubMed ID: 11966741 [TBL] [Abstract][Full Text] [Related]
7. Effect of withdrawal of somatostatin plus growth hormone (GH)-releasing hormone as a stimulus of GH secretion in Cushing's syndrome. Leal-Cerro A; Soto A; Martínez MA; Alvarez P; Isidro L; Casanueva FF; Dieguez C; Cordido F Clin Endocrinol (Oxf); 2002 Dec; 57(6):745-9. PubMed ID: 12460324 [TBL] [Abstract][Full Text] [Related]
8. Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus. Huhn WC; Hartman ML; Pezzoli SS; Thorner MO J Clin Endocrinol Metab; 1993 May; 76(5):1202-8. PubMed ID: 8496311 [TBL] [Abstract][Full Text] [Related]
10. Somatostatin infusion withdrawal: studies in the acute and recovery phase of anorexia nervosa, and in obesity. Pincelli AI; Rigamonti AE; Scacchi M; Cella SG; Cappa M; Cavagnini F; Müller EE Eur J Endocrinol; 2003 Feb; 148(2):237-43. PubMed ID: 12590644 [TBL] [Abstract][Full Text] [Related]
11. Growth Hormone (GH) but not IGF-I-Secretion is Stimulated in Aged Rats by Chronic Hexarelin and GHRP-6 administration. Settembrini B; Figueroa J; Gallardo M; Chiocchio S Endocr Regul; 1998 Mar; 32(1):17-26. PubMed ID: 10407366 [TBL] [Abstract][Full Text] [Related]
13. A pharmacokinetic/pharmacodynamic model for recombinant human growth hormone effects on induction of insulin-like growth factor I in monkeys. Sun YN; Lee HJ; Almon RR; Jusko WJ J Pharmacol Exp Ther; 1999 Jun; 289(3):1523-32. PubMed ID: 10336548 [TBL] [Abstract][Full Text] [Related]
14. Involvement of nitric oxide in the regulation of growth hormone secretion in dogs. Valverde I; Peñalva A; Ghigo E; Casanueva FF; Dieguez C Neuroendocrinology; 2001 Oct; 74(4):213-9. PubMed ID: 11598377 [TBL] [Abstract][Full Text] [Related]
15. Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion. Bowers CY; Granda-Ayala R Endocrine; 2001 Feb; 14(1):79-86. PubMed ID: 11322505 [TBL] [Abstract][Full Text] [Related]
16. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. Jaffe CA; Ho PJ; Demott-Friberg R; Bowers CY; Barkan AL J Clin Endocrinol Metab; 1993 Dec; 77(6):1641-7. PubMed ID: 7903313 [TBL] [Abstract][Full Text] [Related]
18. Pretreatment with growth hormone-releasing peptide-2 directly protects against the diastolic dysfunction of myocardial stunning in an isolated, blood-perfused rabbit heart model. Weekers F; Van Herck E; Isgaard J; Van den Berghe G Endocrinology; 2000 Nov; 141(11):3993-9. PubMed ID: 11089529 [TBL] [Abstract][Full Text] [Related]
19. Accelerated escape from GH autonegative feedback in midpuberty in males: evidence for time-delimited GH-induced somatostatinergic outflow in adolescent boys. Richmond E; Rogol AD; Basdemir D; Veldhuis OL; Clarke W; Bowers CY; Veldhuis JD J Clin Endocrinol Metab; 2002 Aug; 87(8):3837-44. PubMed ID: 12161519 [TBL] [Abstract][Full Text] [Related]
20. Growth hormone responses to growth hormone-releasing hormone and hexarelin in fed and fasted dogs: effect of somatostatin infusion or pretreatment with pirenzepine. Rigamonti AE; Marazzi N; Cella SG; Cattaneo L; Müller EE J Endocrinol; 1998 Feb; 156(2):341-8. PubMed ID: 9518881 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]